|
Attached PDF
In the current report, patients who did not have
a significant decline (20%) in serum HER-2/neu
levels had decreased benefit from trastuzumab-based
therapy. Monitoring changes in serum HER-2 levels
at a median of 1 month after trastuzumab treatment
to predict clinical response may be valuable for identifying
a patient population that might benefit from
additional treatment regimens with other HER-2/
neu-targeted therapies. Currently, although trastuzumabshould not be stopped based on the absence of
a decline in serum HER-2 levels, prospective clinical
trials evaluating the use of other HER-2-directed
therapies (ie, lapatinib, Hsp-90 inhibitor, sheddase
inhibitor) with and without continued trastuzumab
therapy are warranted for patients who do not
achieve a 20% decline in serum HER-2.
|